MetaCap

Immatics N.V. (IMTX) vs Odyssey Therapeutics (ODTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Immatics N.V. is the larger company by market cap ($878.6 million vs $815.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMTX-49.25%ODTX+3.29%
+81%+13%-55%
May 8, 20261 yearNov 20, 2026
IMTX-49.25%ODTX+3.29%
+81%+13%-55%
May 4, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMTX versus ODTX key metrics
MetricIMTXODTX
Share price$5.77$16.96
Market cap$878.58M$815.23M
1-day change-3.03%-7.52%
YTD return-45.05%—
1-year return-43.43%—
5-year return-48.57%—
EPS (TTM)$-1.95$-6.33
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$12.41$29.05
52-week low$5.72$15.10
Distance from 52-week high-53.51%-41.62%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+176.78%+104.42%
Average volume962.74K329.31K
Shares outstanding152.27M48.07M
Employees721100
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Immatics N.V.

IMTX stock →

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 721 employees

About Odyssey Therapeutics

ODTX stock →

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptor–associated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 100 employees

IMTX vs ODTX FAQ

Which is bigger, Immatics N.V. or Odyssey Therapeutics?

Immatics N.V. (IMTX) is larger, with a market capitalization of $878.58M compared with $815.23M for Odyssey Therapeutics (ODTX).

Are Immatics N.V. and Odyssey Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons